Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.51 |
| ▸ | TRPC3 | Q13507 | 1/20 | 0.51 |
| ▸ | TRPC4 | Q9UBN4 | 1/20 | 0.51 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8215131 | 0.91 | SLC2A1 (0.55) | BCHETRPC3TRPC4TRPC5 | |
| SCHEMBL7143750 | 0.82 | BCHE (0.50) | BCHETRPC3TRPC4TRPC5 | |
| SCHEMBL10069525 | 0.80 | — | — | |
| SCHEMBL178883 | 0.78 | BCHE (0.56) | BCHETRPC3TRPC4TRPC5 | |
| Hydrochloric Acid SCHEMBL7817370 | 0.77 | — | — | |
| SCHEMBL8472939 | 0.76 | SLC2A1 (0.44) | — | |
| SCHEMBL178919 | 0.75 | BCHE (0.51) | BCHETRPC3TRPC4TRPC5 | |
| SCHEMBL10069523 | 0.74 | SLC2A1 (0.60) | BCHETRPC3TRPC4TRPC5 | |
| Hydrochloric Acid SCHEMBL5429825 | 0.72 | SLC2A1 (0.43) | — | |
| Hydrochloric Acid SCHEMBL8222196 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120058133-A1 | INHIBITION OF TRNA SYNTHETASES AND THERAPEUTIC APPLICATIONS THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-03-08 | — | — | US | disclosed |
| WO-2000071522-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS METHIONYL T-RNA SYNTHETASE INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2000-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058133-A1 | INHIBITION OF TRNA SYNTHETASES AND THERAPEUTIC APPLICATIONS THEREOF | AARS1, GARS1, TRMT1 | BCHE 4506/4885TRPC3 1951/4885TRPC4 3619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.